breaking news

OVERNIGHT: In late votes, transgender bathroom bill, 10 others sent to House

Commentary: Tackle drug monopolies to bring medication prices down


The news that President Donald Trump takes the anti-baldness drug Propecia has temporarily bumped his war against the pharma sector from the front pages. Before his doctor offered this juicy tidbit, the focus was on Trump’s comment that drug companies were “getting away with murder” and his threat to authorize Medicare to negotiate lower prices.

Wall Street took Trump’s remarks seriously, causing pharma stocks to tank. Pharma CEOs did too. Several pledged to limit future price hikes to 10 percent per year.

Not all pharma execs were cowed, though.

Jeffrey Aronin, the CEO of Marathon Pharmaceuticals, stuck with big pharma’s historic game plan. After Marathon gained approval from the Food and Drug Administration for deflazacort, a treatment for muscular dystrophy that has long been available in other countries for about $1,000 a year, he announced that the drug would cost $89,000 a year in the U.S. When accused of price gouging, he cited research and development costs and pointed out that most of the money comes from insurers.

Both excuses are phony.

Marathon can demand an absurd price because it has a monopoly on deflazacort, an “orphan drug” that treats a rare disease. Under the Orphan Drug Act, the FDA’s approval gave the company the exclusive right to sell the drug in the U.S. for seven years. Marathon is gouging consumers, insurers and public payers simply because it can.

Monopolies are the biggest reason that drug prices in the U.S. are so high. Manufacturers acquire them in a host of ways. Some are legal. Others straddle the line.

The legal means include obtaining patents on new drugs, proving that orphan drugs and unapproved drugs work, and using tweaks such as pill coatings, timed-release formulas and redesigned delivery systems to make patents last longer. The shady means include collusive litigation settlements that stave off generic entry for years, parallel pricing by manufacturers of similar drugs that should be competing and informal agreements among manufacturers not to invade each other’s turf.

Monopolies explain why pharma companies can raise prices on existing medications, something they routinely do. Car-makers can’t charge more for last year’s models. Neither can companies that make computers, cellphones or flat screen TVs. But pharma companies raise prices on existing drugs year after year. Being the sole suppliers, they can set prices as high as they like knowing that they have Medicare, Medicaid, private insurers and consumers over a barrel.

Trump’s idea of letting Medicare bargain over prices won’t help much because Medicare can’t really refuse to pay for drugs that are overpriced. The first time it offers cost as a reason for refusing to cover a medication, cries of “rationing” and “death panels” will fill the air. That’s the third rail of health care politics, so Medicare won’t go there.

A better approach would be to do away with monopolies, starting with the legal ones.

Several economists have proposed that patents be replaced with prizes. For example, a company that spent $100 million researching a new drug might receive a check for $500 million from the treasury after the drug was approved. The multiplier would preserve the incentive to innovate while public funding would spread the burden across all taxpayers — who bear much of the cost of medical research already — instead of concentrating it on the much smaller population of sick people who need a particular drug but may be the least able to afford it.

Drugs would then sell cheaply at pharmacies because all manufacturers would be free to make and sell all approved medications. It’s time to explore this option, which would work for old drugs and orphan drugs, too.

Trump will have to tackle shady monopolies. To do this, he’ll have to put pharma companies in the crosshair of the antitrust division of the Justice Department. That’s not a popular idea in Republican circles, but as long as drug companies know they can collude, prices will remain high.

Right now, Trump is scoring points by using his pulpit to bully pharma companies. But we’ll know that he’s serious about getting prices under control when he tackles drug monopolies.

Silver is a professor of law at the University of Texas and a co-author of the forthcoming book “After Obamacare: Making American Health Care Better and Cheaper.”



Reader Comments ...


Next Up in Opinion

Commentary: Why the ‘genius’ of South Terminal works for millennials
Commentary: Why the ‘genius’ of South Terminal works for millennials

This past weekend, I had the pleasure of heading home to Cincinnati on the Allegiant nonstop flight out of the South Terminal at Austin-Bergstrom International Airport. My experience heading home included a ticketing agent being cussed at by a passenger who had no clue how to get to the new terminal; a nonexistent TSA PreCheck (oh, the agony!); and...
Herman: Again, Texas’ bathroom bill a solution in search of a problem
Herman: Again, Texas’ bathroom bill a solution in search of a problem

One of the more anticipated summer re-runs at Your Texas Capitol aired Tuesday as GOP senators, against the advice of cops, advanced the bathroom bill. That’s the thing with reruns — they always come out the same. Or do they? We’ll find out when the bill gets to the House. During the regular session, the House OK’d a version...
Opinion: Liberal teachers’ union wrong to equate freedom with racism

Randi Weingarten, president of the nation’s second-largest teachers union, the American Federation of Teachers, used a speech last week to brand the education choice movement as racist. She also got personal, trying to pin the racist label onto Secretary of Education Betsy DeVos because DeVos is a passionate supporter of parents being able to...
Commentary: Trump didn’t give Scouts a speech. It was a political rally
Commentary: Trump didn’t give Scouts a speech. It was a political rally

Like many young Americans, I grew up attending weekly meetings as a member of Troop 405 in my hometown of Georgetown. I loved my time in Scouts. We went on amazing trips. Over many years, I learned the values Scouting instils in America’s youth. After reading over President Trump’s transcript and watching highlights of his Jamboree speech...
David Brooks: How cool works in America today
David Brooks: How cool works in America today

If you grew up in the 20th century, there’s a decent chance you wanted to be like Miles Davis, Billie Holiday, Humphrey Bogart, Albert Camus, Audrey Hepburn, James Dean or Jimi Hendrix. In their own ways, these people defined cool. The cool person is stoical, emotionally controlled, never eager or needy, but instead mysterious, detached and self-possessed...
More Stories